EA202000248A1 - ANTI-SARS-CoV-2 VIRAL ANTIPROVIR - Google Patents
ANTI-SARS-CoV-2 VIRAL ANTIPROVIRInfo
- Publication number
- EA202000248A1 EA202000248A1 EA202000248A EA202000248A EA202000248A1 EA 202000248 A1 EA202000248 A1 EA 202000248A1 EA 202000248 A EA202000248 A EA 202000248A EA 202000248 A EA202000248 A EA 202000248A EA 202000248 A1 EA202000248 A1 EA 202000248A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antiprovir
- cov
- sars
- viral
- coronovirus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к новому противо-SARS-CoV-2 вирусному средству Антипровир, предназначенному для профилактики и лечения короновирусного заболевания COVID-19. Применение фармацевтической композиции, в том числе Апротекс, Гордокс и Аэрус, включающие в качестве активного компонента апротинин и вспомогательные вещества, в качестве противо-SARS-CoV-2 вирусного лекарственного средства Антипровир для профилактики и лечения короновирусного заболевания COVID-19. Лекарственное средство Антипровир для профилактики и лечения короновирусного заболевания COVID-19 представляет собой фармацевтическую композицию, содержащую 0,1-0,2 вес.% апротинина, необязательно 0,2-1,0 вес.% вспомогательных веществ и остальное - вода для инъекций.The invention relates to a new anti-SARS-CoV-2 viral agent Antiprovir, intended for the prevention and treatment of coronovirus disease COVID-19. The use of a pharmaceutical composition, including Aprotex, Gordox and Aerus, including aprotinin and excipients as an active ingredient, as an anti-SARS-CoV-2 viral drug Antiprovir for the prevention and treatment of coronovirus disease COVID-19. The drug Antiprovir for the prevention and treatment of coronovirus disease COVID-19 is a pharmaceutical composition containing 0.1-0.2 wt.% aprotinin, optionally 0.2-1.0 wt.% excipients and the rest is water for injection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU2020/000328 WO2021221532A1 (en) | 2020-04-30 | 2020-07-03 | Sars-cov-2 antiviral drug antiprovir |
RU2020000328 | 2020-07-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202000248A1 true EA202000248A1 (en) | 2022-01-31 |
Family
ID=80631221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202000248A EA202000248A1 (en) | 2020-07-03 | 2020-07-03 | ANTI-SARS-CoV-2 VIRAL ANTIPROVIR |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202000248A1 (en) |
-
2020
- 2020-07-03 EA EA202000248A patent/EA202000248A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000798A (en) | Functionalized peptides as antiviral agents. | |
WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
MX2023005984A (en) | Novel spiropyrrolidine derived antiviral agents. | |
RU2329050C2 (en) | Combination of cytochrome-p450-dependent protease inhibitors | |
EA200602130A1 (en) | SUBSTITUTED ARYLACYLTIOMETRIC AND RELATED COMPOUNDS; VIRUS REPLICATION INHIBITORS | |
AR032556A1 (en) | IMMEDIATE ACTION DRUG FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
MX2023005983A (en) | Novel spiropyrrolidine derived antiviral agents. | |
EA201490163A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
EA202190960A1 (en) | CONDENSED PYRROLINES THAT ACT AS INHIBITORS OF UBIKVITIN SPECIFIC PROTEASE 30 (USP30) | |
MX2023001756A (en) | Functionalized peptides as antiviral agents. | |
EA202000347A1 (en) | ANTI-SARS-CoV-2 VIRAL AGENT ANTIPROVIR | |
SE9901573D0 (en) | New compounds | |
RU2012157328A (en) | MEDICINAL PRODUCT FOR PREVENTIVE AND / OR THERAPEUTIC TREATMENT OF DEMENTIA BY ALZHEIMER TYPE | |
EA202190544A1 (en) | APPLICATION OF RILUZOL TABLETS DISPOSING IN THE ORAL CAVITY FOR THE TREATMENT OF DISEASES | |
EA202000248A1 (en) | ANTI-SARS-CoV-2 VIRAL ANTIPROVIR | |
EA202000165A1 (en) | ANTI-PHK VIRAL, INCLUDING ANTI-SARS-CoV-2 VIRAL PHARMACEUTICAL COMPOSITION AVIFAVIR | |
AR046146A1 (en) | TRANSDERMAL PHARMACEUTICAL FORMULATIONS FOR SPRAYING THAT INCLUDE AN ACTIVE AGENT, A VP / VA COPOLYMER AND A NON-WATER VEHICLE | |
SE9901572D0 (en) | New compounds | |
EA200400348A1 (en) | CYPLATINE COMPOSITIONS OF REDUCED TOXICITY AND METHODS OF THEIR APPLICATION | |
CR20230192A (en) | Solid formulation | |
EA202193190A1 (en) | COMPOSITION INCLUDING PRIDOPIDINE AND ITS ANALOGUE FOR THE TREATMENT OF HUNTINGTON'S DISEASE AND ITS SYMPTOMS | |
RU2020124373A (en) | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR CATARACT, MEDICAL COMPOSITION FOR THE PREVENTION AND/OR TREATMENT OF CATARACT, APPLICATION OF A PPAR ACTIVATOR FOR THE SAME PURPOSE AND EYE DROPS | |
KR950702413A (en) | Method of using 2- (4- (4-chlorophenyl) cyclohexyl) -3-hydroxy-1,4-naphthoquinone for cancer treatment (USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL)- 3-HYDROXY-1,4-NAPHTHOQUINONE FOR THE TREATMENT OF CANCER) | |
EA201900293A3 (en) | TRANSDERMAL DRUG FOR TREATMENT AND PREVENTION OF DISEASES OF JOINTS AND SOFT TISSUES | |
DE602006016168D1 (en) | 1,3,5-triazepine-diones for the treatment of malaria |